ReviewFEMS microbiology reviews2021
The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.
Review in FEMS microbiology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 2 syntheses or guidelines pooled it, 334 citations in OpenAlex.
- Harnessing probiotics against candidiasis: a systematic review of experimental and mechanistic evidence.Frontiers in cellular and infection microbiology · 2026Pooled it
- Evaluating the Efficacy of Rose Bengal as a Photosensitizer in Antimicrobial Photodynamic Therapy AgainstInternational journal of molecular sciences · 2025Pooled it
- Evaluation of the Antifungal Effect of Lacticaseibacillus rhamnosus GG against Oral candidiasis in Healthy Sprague-Dawley Rats.Journal, genetic engineering & biotechnology · 2026Article
- FgNup2 regulates nuclear import of the histone H2B monoubiquitination enzyme by stabilizing the FgImpα-FgBre1 complex to mediate pathogenicity in Fusarium graminearum.PLoS pathogens · 2026Article
- Emerging antifungal strategies against Candida albicans using metal-organic frameworks and novel therapeutics: Opportunities and challenges.Journal of food and drug analysis · 2026Review
- Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data.Journal of fungi (Basel, Switzerland) · 2026Review
- Ergosterol from Yeasts PromotesInternational journal of molecular sciences · 2026Article
- [Age-Related Changes in the Oral Microbiota].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Review
- Expansion, functional diversification, and gene fusion events in the Ato protein family.iScience · 2026Article
- Article
- Biofilm formation efficiency by Candida species isolated from gastric mucosa of intragastric balloon patient under extremely low pH.Folia microbiologica · 2026Article
- Article
- Species distribution and antifungal susceptibility patterns of oral Candida colonization and infection in β-thalassemia major patients.BMC oral health · 2026Article
- In Vitro Antifungal and Wound-Healing Potential ofAntibiotics (Basel, Switzerland) · 2026Article
- Drug-resistant clinicalAntimicrobial agents and chemotherapy · 2026Article
- From Identification to Resistance: Contemporary Insights into Candida Species Causing Vaginitis.Cureus · 2026Review
- Article
- Protective effects ofJournal of microbiology and biotechnology · 2026Article
- Exometabolome variation in the fungal pathogen of humansApplied and environmental microbiology · 2026Article
- Characterization of the vaginal microbiome and its metabolic potential in Colombian patients with recurrent vulvovaginal candidiasis.Medical mycology · 2026Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 13 institutions in 8 countries.
Funding
Abstract
Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.